Anne Letsch

List of Publications by Year
in descending order

46	1,774	304743	265206
papers	citations	22 h-index	42 g-index

47	47	47	2348
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood, 2009, 113, 6541-6548.	1.4	275
2	CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood, 2002, 100, 2132-2137.	1.4	245
3	Natural T cell immunity against cancer. Clinical Cancer Research, 2003, 9, 4296-303.	7.0	154
4	Quantitative Detection of Circulating Tumor Cells in Cutaneous and Ocular Melanoma and Quality Assessment by Real-Time Reverse Transcriptase-Polymerase Chain Reaction. Clinical Cancer Research, 2004, 10, 1605-1612.	7.0	96
5	Quantification and characterization of specific T-cells by antigen-specific cytokine production using ELISPOT assay or intracellular cytokine staining. Methods, 2003, 31, 143-149.	3.8	88
6	Functional CCR9 Expression Is Associated with Small Intestinal Metastasis. Journal of Investigative Dermatology, 2004, 122, 685-690.	0.7	84
7	Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides. International Journal of Cancer, 2003, 104, 188-194.	5.1	74
8	Flow cytometric determination of intracellular or secreted IFNÎ³ for the quantification of antigen reactive T cells. Journal of Immunological Methods, 2001, 251, 101-108.	1.4	67
9	Identification of a Highly Immunogenic HLA-A*01-Binding T Cell Epitope of WT1. Clinical Cancer Research, 2006, 12, 7476-7482.	7.0	53
10	Harmonization of the intracellular cytokine staining assay. Cancer Immunology, Immunotherapy, 2012, 61, 967-978.	4.2	47
11	High frequencies of circulating melanoma-reactive CD8+ T cells in patients with advanced melanoma. International Journal of Cancer, 2000, 87, 659-664.	5.1	43
12	Bone marrow contains melanoma-reactive CD8+ effector T cells and, compared with peripheral blood, enriched numbers of melanoma-reactive CD8+ memory T cells. Cancer Research, 2003, 63, 5582-6.	0.9	42
13	Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2. Blood, 2006, 107, 3205-3211.	1.4	40
14	Rational peptide-based tumour vaccine development and T cell monitoring. Seminars in Cancer Biology, 2003, 13, 423-429.	9.6	36
15	CMVâ€specific central memory T cells reside in bone marrow. European Journal of Immunology, 2007, 37, 3063-3068.	2.9	32
16	Human peripheral blood and bone marrow Epsteinâ€“Barr virusâ€specific Tâ€cell repertoire in latent infection reveals distinct memory Tâ€cell subsets. European Journal of Immunology, 2010, 40, 1566-1576.	2.9	32
17	Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients. International Journal of Cancer, 2003, 105, 221-225.	5.1	31
18	Favorable prognostic influence of T-box transcription factor Eomesodermin in metastatic renal cell cancer patients. Cancer Immunology, Immunotherapy, 2016, 65, 181-192.	4.2	27

#	Article	IF	Citations
19	Long-term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides. International Journal of Cancer, 2002, 99, 403-408.	5.1	26
20	Wilms tumor protein 1 (WT1) â€" Not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma. Gynecologic Oncology, 2016, 140, 494-502.	1.4	26
21	â€œWilms Tumor Protein 1â€•(WT1) Peptide Vaccination-induced Complete Remission in a Patient With Acute Myeloid Leukemia Is Accompanied by the Emergence of a Predominant T-cell Clone Both in Blood and Bone Marrow. Journal of Immunotherapy, 2011, 34, 85-91.	2.4	24
22	T cell responses against tumor associated antigens and prognosis in colorectal cancer patients. Journal of Translational Medicine, 2005, 3, 3.	4.4	23
23	Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3Î² sequence associated with remission in one patient is detectable in other vaccinated patients. Cancer Immunology, Immunotherapy, 2012, 61, 313-322.	4.2	17
24	Peptide vaccination after repeated resection of metastases can induce a prolonged relapse-free interval in melanoma patients. International Journal of Cancer, 2005, 114, 936-941.	5.1	16
25	Early integration of palliative/supportive cancer careâ€"healthcare professionalsâ€™ perspectives on the support needs of cancer patients and their caregivers across the cancer treatment trajectory. Supportive Care in Cancer, 2017, 25, 1621-1627.	2.2	16
26	Cancer patients' expectations when undergoing extensive molecular diagnosticsâ€"A qualitative study. Psycho-Oncology, 2020, 29, 423-429.	2.3	16
27	Early palliative care for those who care: A qualitative exploration of cancer caregiversâ€™ information needs during hospital stays. European Journal of Cancer Care, 2019, 28, e12990.	1.5	15
28	Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination. Journal of Translational Medicine, 2010, 8, 5.	4.4	13
29	Human Bone Marrow as a Source to Generate CMV-specific CD4+ T Cells With Multifunctional Capacity. Journal of Immunotherapy, 2009, 32, 907-913.	2.4	12
30	Information, communication, and cancer patientsâ€™ trust in the physician: what challenges do we have to face in an era of precision cancer medicine?. Supportive Care in Cancer, 2021, 29, 2171-2178.	2.2	12
31	Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy. BMC Cancer, 2015, 15, 784.	2.6	11
32	Early integration of palliative cancer care: patientsâ€™ and caregiversâ€™ challenges, treatment preferences, and knowledge of illness and treatment throughout the cancer trajectory. Supportive Care in Cancer, 2018, 26, 921-931.	2.2	11
33	Specific Central Memory T Cells in the Bone Marrow of Patients Immunized Against Tyrosinase Peptides. Journal of Immunotherapy, 2006, 29, 201-207.	2.4	10
34	Addition of GM-CSF to a peptide/KLH vaccine results in increased frequencies of CXCR3-expressing KLH-specific T cells. Cancer Immunology, Immunotherapy, 2007, 56, 391-396.	4.2	10
35	Psychometric Evaluation of the German Version of the Demoralization Scale-II and the Association Between Demoralization, Sociodemographic, Disease- and Treatment-Related Factors in Patients With Cancer. Frontiers in Psychology, 2021, 12, 789793.	2.1	10
36	Human bone marrow contains a subset of quiescent early memory CD8⁺ T cells characterized by high CD127 expression and efflux capacity. European Journal of Immunology, 2014, 44, 3532-3542.	2.9	9

#	Article	IF	Citations
37	Identification of truncated chemokine receptor 7 in human colorectal cancer unable to localize to the cell surface and unreactive to external ligands. International Journal of Cancer, 2008, 123, 1565-1572.	5.1	8
38	Cancer testis antigen Cyclin A1 harbors several HLA-A*02:01-restricted T cell epitopes, which are presented and recognized in vivo. Cancer Immunology, Immunotherapy, 2020, 69, 1217-1227.	4.2	8
39	Clinically misinterpreted melanoma metastases can correctly be diagnosed by ultrasound-guided fine needle aspiration cytology. European Journal of Dermatology, 2011, 21, 238-241.	0.6	5
40	Long term presence of a single predominant tyrosinaseâ€specific Tâ€cell clone associated with disease control in a patient with metastatic melanoma. International Journal of Cancer, 2010, 126, 2497-2502.	5.1	4
41	Intracellular Cytokine Staining. , 2005, , 175-182.		3
42	Lymphoma Cells Are Highly Sensitive to Cytotoxic T-Cell-Killing Despite Presence of Multiple Resistance Mechanisms. Journal of Immunotherapy, 2004, 27, S45.	2.4	1
43	Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q). Annals of Hematology, 2021, 100, 1463-1471.	1.8	1
44	Application of a Short Tandem Repeat Based PCR Assay for Chronological Monitoring of Myelodysplastic Syndrome (MDS) Patients with Deletion of Chromosome 5q Following Lenalidomide Treatment. Blood, 2015, 126, 2891-2891.	1.4	1
45	Malignant Melanoma â€“ Clinical Development of Peptide-Based Melanoma Vaccines. , 2005, 39, 171-180.		0
46	TP53 Mutations Detected By Next-Generation Deep-Sequencing In Patients With Myelodysplastic Syndrome and Isolated Deletion (5q): Results From a German Multicenter Trial. Blood, 2013, 122, 2759-2759.	1.4	0